VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | The role of PET/CT in assessing early treatment response in patients with NDMM

Charalampos Charalampous, MD, Mayo Clinic, Rochester, MN, comments on the role of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma (NDMM). In a recent study, it was shown that PET/CT negativity at six months is predictive of better progression-free survival (PFS), time to next treatment, and overall survival (OS). This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter